The Significance of Enzyme Immunoassay for the Assessment of Hepatitis B Virus Core-Related Antigen following Liver Transplantation

Masumi Fujimoto, Tatsuki Ichikawa, Kazuhiko Nakao, Hisamitsu Miyaaki, Hidetaka Shibata, Susumu Eguchi, Mitsuhisa Takatsuki, Shinya Nagaoka, Hiroshi Yatsuhashi, Takashi Kanematsu, Katsumi Eguchi
2009 Internal medicine (Tokyo. 1992)  
Purpose Recently, a new enzyme immunoassay for the detection of hepatitis B virus (HBV) core-related antigen (HBcrAg) has been reported. In this study, we proposed to account for feasibility of HBcrAg assay, and discuss the dynamics of HBV seen in patients following HBV-related living donor liver transplantation (LDLT). Methods and results This study involved 12 patients; 11 patients had positive serum HBcrAg, and 6 patients had negative HBV-DNA. In the post-operation period, all cases were
more » ... all cases were negative for HBV-DNA and HBsAg in sera under prophylaxis therapy. At post-operation, 5 of the 12 had positive serum HBcrAg, and at stable state, 6 had positive serum HBcrAg postoperatively. The mean levels of HBcrAg following LDLT were significantly lower than those seen in the preoperative-operation stage. Conclusion This enzyme immunoassay is a readily utilizable marker of HBV replication in the post transplantation stage. Furthermore, the evaluation of HBV activity by HBcrAg assay must be studied to determine the appropriate prophylaxis for controlling replication of HBV following LDLT. pan), was a major breakthrough in controlling HBV recurrence in patients who received transplants for HBV-related liver disease. The ideal recurrence rate for HBV (<10%), has been observed in patients receiving HBIG and Lam combination prophylaxis versus just HBIG monotherapy (2, 3) or Lam monotherapy (4, 5). Lam monotherapy has been shown to be ineffective in controlling recurring HBV, and the long term administration of HBIG was necessary (6, 7). Therefore, presently, continuous combination therapy is the standard prophylaxis in the control of HBV recurrence following HBV-related LT.
doi:10.2169/internalmedicine.48.2000 pmid:19755758 fatcat:4gv3sa6kdrfcvedfjuofgk4x6e